Characterization of the RNA recognition mode of hnRNP G extends its role in SMN2 splicing regulation.

Moursy A, Allain FH, Cléry A. Nucleic Acids Res. 2014 Apr 1.

07 April 2014

Morphological and functional remodelling of the neuromuscular junction by skeletal muscle PGC-1α.

Arnold AS, Gill J, Christe M, Ruiz R, McGuirk S, St-Pierre J, Tabares L, Handschin C. Nat Commun. 2014 Apr 1;5:3569.

02 April 2014

Modulation of PGC-1α activity as a treatment for metabolic and muscle-related diseases.

Svensson K, Handschin C. Drug Discov Today. 2014 Mar 12. Review

19 März 2014

Molecular targets to treat muscular dystrophies.

Kinter J, Sinnreich M. Swiss Med Wkly. 2014 Feb 19.

24 Februar 2014

Injection of a Soluble Fragment of Neural Agrin (NT-1654) Considerably Improves the Muscle Pathology Caused by the Disassembly of the Neuromuscular Junction.

Hettwer S, Lin S, Kucsera S, Haubitz M, Oliveri F, Fariello RG, Ruegg MA, Vrijbloed JW. PLoS One. 2014 Feb 10;9(2)

24 Februar 2014

The transcriptional coactivator PGC-1α is dispensable for chronic overload-induced skeletal muscle hypertrophy and metabolic remodeling.

Pérez-Schindler J, Summermatter S, Santos G, Zorzato F, Handschin C. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20314-9.

20 Dezember 2013

MAR-mediated integration of plasmid vectors for in vivo gene transfer and regulation.

Puttini S, van Zwieten RW, Saugy D, Lekka M, Hogger F, Ley D, Kulik AJ, Mermod N. BMC Mol Biol. 2013 Dec 2;14:26.

10 Dezember 2013

Functional crosstalk of PGC-1 coactivators and inflammation in skeletal muscle pathophysiology.

Eisele PS, Handschin C. Semin Immunopathol. 2013 Nov 21.

01 Dezember 2013

Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival.

Saxena S, Roselli F, Singh K, Leptien K, Julien JP, Gros-Louis F, Caroni P. Neuron. 2013 Oct 2;80(1):80-96.

15 Oktober 2013

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

Ruegg UT. Curr Opin Neurol. 2013 Oct;26(5):577-84.

01 Oktober 2013